Galenicum enters agreement with Optibiotix to commercialise LPLDL® strain
November 10, 2017
Galenicum Special Ingredients (Galenicum) is partnering with Optibiotix, a life sciences company specialising in the modulation of the human microbiome, to commercialise products that will address health concerns such as high blood pressure and cholesterol.
The supply agreement provides Galenicum with a license to commercialise Stop&Go Cardiocare™, a nutritional supplement containing OptiBiotix’s LPLDL®, in the Middle East, Chile, Peru and Spain. Stop&Go Cardiocare™ will join Galenicum’s established STOP&GO product range as a holistic, science-backed formulation for addressing issues such as high blood pressure and cholesterol.
OptiBiotix’s LPLDL® is a third-generation bacterial strain and probiotic that aids elements of cardiovascular and physiological wellbeing by modulating the human microbiome, contributing to better overall heart health. It has been shown in randomised controlled human studies to be safe and well tolerated by human subjects, delivering tangible health benefits, reducing cardiovascular risk factors and supporting overall heart wellness.
Stephen O’Hara, Optibiotix CEO, said: “We selected Galenicum for its outstanding reputation as a pharmaceutical industry leader, impressive sales growth record and access to markets we have yet to explore. By combining our expertise in microbiome modulation with Galenicum’s international renown, manufacturing capacity and scale, we will make LPLDL® a leading global brand”.